Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Cancer Vaccines Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences
Vaccines Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2017

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice

Foote, J. B., Kok, M., Leatherman, J. M., Armstrong, T. D., Marcinkowski, B. C., Ojalvo, L. S., Kanne, D. B., Jaffee, E. M., Dubensky, T. W. & Emens, L. A. Jun 1 2017 In : Cancer Immunology Research. 5, 6, p. 468-479 12 p.

Research output: Research - peer-reviewArticle

OX40 Receptor
Interferons
Immunity
T-Lymphocytes
Growth

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Dirix, L. Y., Takacs, I., Jerusalem, G., Nikolinakos, P., Arkenau, H. T., Forero-Torres, A., Boccia, R., Lippman, M. E., Somer, R., Smakal, M., Emens, L. A., Hrinczenko, B., Edenfield, W., Gurtler, J., von Heydebreck, A., Grote, H. J., Chin, K. & Hamilton, E. P. Oct 23 2017 (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-16 16 p.

Research output: Research - peer-reviewArticle

Breast Neoplasms
Antibodies
Neoplasms
avelumab
Therapeutics

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B. & Marincola, F. M. Aug 1 2017 In : European Journal of Cancer. 81, p. 116-129 14 p.

Research output: Research - peer-reviewReview article

Immunotherapy
Neoplasms
Therapeutics
Biomarkers
Survival

PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast

Thompson, E. D., Taube, J. M., Asch-Kendrick, R. J., Ogurtsova, A., Xu, H., Sharma, R., Meeker, A., Argani, P., Emens, L. A. & Cimino-Mathews, A. Nov 1 2017 In : Modern Pathology. 30, 11, p. 1551-1560 10 p.

Research output: Research - peer-reviewArticle

Lobular Carcinoma
Breast
Tumor-Infiltrating Lymphocytes
Breast Neoplasms
Neoplasms

Report on the third FDA–AACR oncology dose-finding workshop

Emens, L. A., Bruno, R., Rubin, E. H., Jaffee, E. M. & McKee, A. E. Dec 1 2017 In : Cancer Immunology Research. 5, 12, p. 1058-1061 4 p.

Research output: Research - peer-reviewArticle

Education
Practice Guidelines
Patient Selection
Biomarkers
Therapeutics